Showing results (41-50 of 74) with videos related to
Sort By:
Pageof 8
Dermatology and Therapy|March 21, 2024
Management of Patients Affected by Moderate-to-Severe Atopic Dermatitis with JAK Inhibitors in Real-World Clinical Practice: An Italian Delphi ConsensusLuigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.Dermatology Practical & Conceptual|December 9, 2024
Anti-IL-17/23 Drugs for the Treatment of Moderate-to-Severe Hidradenitis Suppurativa in Patients With Concomitant Psoriasis: A Multicenter Retrospective StudyLuigi Gargiulo, Luciano Ibba, Alessandra Narcisi, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|September 26, 2022
Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52-week multicentre retrospective study-IL PSO (Italian landscape psoriasis)Alessandra Narcisi, Mario Valenti, Luigi Gargiulo, et al.The Journal of Dermatological Treatment|January 27, 2025
Safety of interleukin inhibitors in patients with plaque psoriasis and history of neoplasms: a multicenter retrospective study - IL PSO (Italian landscape psoriasis)Mario Valenti, Luciano Ibba, Sara Di Giulio, et al.Frontiers in Immunology|January 26, 2024
Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses - IL PSO (Italian landscape psoriasis)Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.Journal of Clinical Medicine|January 23, 2024
Drug Survival of Upadacitinib and Predicting Factors of Discontinuation in Adult Patients Affected by Moderate-to-Severe Atopic Dermatitis: An Italian Multicenter AnalysisElena Pezzolo, Michela Ortoncelli, Silvia Mariel Ferrucci, et al.Dermatology and Therapy|May 15, 2024
Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study-IL PSO (Italian Landscape Psoriasis)Mario Valenti, Luigi Gargiulo, Luciano Ibba, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|January 25, 2023
Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS)Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.Frontiers in Medicine|July 20, 2023
Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study-IL PSO (Italian landscape psoriasis)Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.Dermatology and Therapy|June 5, 2026
Beyond Psoriasis Area and Severity Index and Body Surface Area: An Italian Delphi Consensus on the Definition of Moderate PsoriasisLuigi Gargiulo, Antonio Costanzo, Piergiorgio Malagoli, et al.Pageof 8